Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6,530 MXN
Change Today -57.52 / -0.87%
Volume 136.0
BIIB* On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:09 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Paul J. Clancy

Chief Financial Officer and Executive Vice President of Finance, Biogen Inc.
AgeTotal Calculated CompensationThis person is connected to 27 board members in 2 different organizations across 4 different industries.

See Board Relationships
52$4,486,256
As of Fiscal Year 2013

Background*

Mr. Paul J. Clancy has been the Chief Financial Officer and Executive Vice President of Finance at Biogen Idec Inc. and Biogen Idec Ma Inc. since August 13, 2007. Mr. Clancy has held several senior executive positions since joining Biogen Idec in 2001, including Vice President of Business Planning, Portfolio Management and US Marketing. He served as Senior Vice President of finance at Biogen Idec, with responsibilities for leading the treasury, tax, investor relations ...

Read Full Background

Corporate Headquarters*

225 Binney Street
Cambridge, Massachusetts 02142

United States

Phone: 617-679-2000
Fax: --

Board Members Memberships*

2013-Present
Director and Chairman of Audit Committee
2015-Present
Director

Education*

MBA
Columbia Business School
BS
Babson College
BSBA
Babson College

Other Affiliations*

Annual Compensation*

Salary$745,223
Total Annual Compensation$745,223

Stock Options*

Restricted Stock Awards$2,808,961
All Other Compensation$221,043
Exercised Options125,815
Exercised Options Value$23,271,876
Total Value of Options$23,271,876
Total Number of Options125,815

Total Compensation*

Total Annual Cash Compensation$1,649,524
Total Short Term Compensation$745,223
Other Long Term Compensation$3,030,004
Total Calculated Compensation$4,486,256
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB*:MM $6,530.00 MXN -57.52

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Lamberto Andreotti Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee
Bristol-Myers Squibb Company
$1.7M
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
$1.3M
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Lars Rebien Sørensen Chief Executive Officer and Member of Executive Management
Novo Nordisk A/S
kr15.2M
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
¥170.0M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.